HC Wainwright Estimates BioNTech’s Q1 Earnings (NASDAQ:BNTX)

BioNTech SE Sponsored ADR (NASDAQ:BNTX) – Equities researchers at HC Wainwright decreased their Q1 2026 earnings per share (EPS) estimates for BioNTech in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($2.41) per share for the quarter, down from their previous forecast of ($2.27). HC Wainwright has a “Buy” rating and a $130.00 price objective on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech’s Q2 2026 earnings at ($2.43) EPS, Q3 2026 earnings at $0.69 EPS, Q4 2026 earnings at ($0.42) EPS and FY2026 earnings at ($4.57) EPS.

Several other equities analysts also recently commented on the company. UBS Group raised BioNTech to a “hold” rating in a research report on Thursday, December 4th. TD Cowen lowered their price target on BioNTech from $116.00 to $94.00 and set a “hold” rating for the company in a report on Wednesday, March 11th. Berenberg Bank restated a “buy” rating on shares of BioNTech in a research note on Friday, January 23rd. Wall Street Zen lowered shares of BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $171.00 price target on shares of BioNTech in a research report on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, BioNTech has a consensus rating of “Moderate Buy” and a consensus price target of $133.07.

BioNTech Price Performance

Shares of BioNTech stock opened at $89.42 on Thursday. The stock has a market cap of $22.47 billion, a price-to-earnings ratio of -17.06 and a beta of 1.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.49 and a current ratio of 7.54. The stock has a 50 day moving average price of $102.32 and a 200-day moving average price of $101.33. BioNTech has a one year low of $79.52 and a one year high of $124.00.

Institutional Investors Weigh In On BioNTech

A number of large investors have recently added to or reduced their stakes in the business. Hsbc Holdings PLC purchased a new position in shares of BioNTech during the fourth quarter valued at approximately $4,969,000. Rockefeller Capital Management L.P. lifted its position in shares of BioNTech by 328.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock worth $177,000 after purchasing an additional 1,423 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its position in BioNTech by 1,012.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock valued at $53,000 after buying an additional 506 shares during the last quarter. Sankala Group LLC acquired a new stake in shares of BioNTech during the fourth quarter valued at about $248,000. Finally, Virtu Financial LLC lifted its stake in shares of BioNTech by 163.9% in the fourth quarter. Virtu Financial LLC now owns 11,244 shares of the company’s stock worth $1,070,000 after acquiring an additional 6,984 shares in the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.